187,897 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 187,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,533,000. Jefferies Financial Group Inc. owned 0.06% of Amicus Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of FOLD. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics in the 4th quarter worth $29,000. Covestor Ltd raised its holdings in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 2,312 shares during the period. GF Fund Management CO. LTD. bought a new position in Amicus Therapeutics in the 4th quarter worth $59,000. GAMMA Investing LLC raised its holdings in Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 7,007 shares during the period. Finally, Bryce Point Capital LLC bought a new position in Amicus Therapeutics in the 1st quarter worth $100,000.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $6.32 on Monday. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The business’s 50-day simple moving average is $6.05 and its two-hundred day simple moving average is $7.42. The stock has a market cap of $1.95 billion, a PE ratio of -52.66 and a beta of 0.53. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

Analysts Set New Price Targets

FOLD has been the topic of a number of recent research reports. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Wall Street Zen raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group decreased their price target on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.